Review of Fluconazole Treatment and Prophylaxis for Invasive Candidiasis in Neonates

Area of Science:

• Neonatal Medicine
• Infectious Diseases
• Pharmacology

Background:

• Invasive candidiasis is a significant cause of hospital-acquired infections in preterm infants, with high mortality rates.
• Current guidelines exist for antifungal use in neonatal intensive care units (NICUs), but practices vary regarding fluconazole.
• There is a need for optimized treatment and prevention strategies for high-risk infants.

Purpose of the Study:

• To review fluconazole's activity, pharmacokinetics, and efficacy in neonates.
• To evaluate different dosing strategies for fluconazole in the neonatal population.
• To compare fluconazole with alternative treatments for invasive candidiasis in infants.

Main Methods:

• Literature review and evaluation of existing studies on fluconazole in neonates.
• Analysis of fluconazole's pharmacokinetic properties relevant to infant physiology.
• Comparative assessment of fluconazole dosing regimens and alternative antifungal therapies.

Main Results:

• Fluconazole demonstrates specific activity against Candida species relevant to neonatal infections.
• Pharmacokinetic data highlights the importance of appropriate dosing in preterm infants due to altered drug metabolism.
• Literature evaluation provides insights into the effectiveness of various fluconazole strategies compared to other antifungals.

Conclusions:

• Optimized fluconazole dosing is crucial for effective prophylaxis and treatment of invasive candidiasis in neonates.
• Understanding fluconazole pharmacokinetics is essential for tailoring therapy to individual infant needs.
• Evidence supports fluconazole's role in managing neonatal candidiasis, with ongoing evaluation of optimal strategies.